GLP-1 weight-loss drugs are cutting calories… and grocery bills, according to a new study from Cornell and Numerator.

Axios Visuals The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab. Why it matters: The ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

2024 — Taking anti-obesity drugs has led some U.S. adults to throw away more food than they tossed before starting the medications, a new study has ...

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin antibody ... our pipeline of obesity drug candidates and has potential ...

COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy ... Wegovy is the first-to-market in a new class of highly effective weight-loss drugs. But analysts say that ...

Eli Lilly has launched a new website-based access programme for some drugs like its new obesity therapy Zepbound ... platforms could violate federal anti-kickback laws. In a new white paper ...

These high-carb foods can enhance your athletic performance and recovery, help you gain weight, boost your metabolism, and ...

The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s.

I applaud the Biden administration’s recent moves to make these anti-obesity drugs more accessible to people on Medicaid and ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...